Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
KYTHERA BIOPHARMACEUTICALS INC (KYTH)
|
|
Income Statement |
|
|
|
Standardized | As Reported |
Annual | Quarterly | TTM |
|
In millions, except per share items | Jun-30-15 | Mar-31-15 | Dec-31-14 | Sep-30-14 | Jun-30-14 | Mar-31-14 | Dec-31-13 | Sep-30-13 |
| 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
Product sales, net | 0.3 | | 132.4 | | | | 50.5 | |
Product sales, net growth | | | 162.3% | | | | | |
Operating expenses: | | | | | | | | |
Cost of sales | 0.0 | | | | | | | |
In-process research and development | | | | | | 52.8 | | |
Research and development | 11.2 | 15.3 | 13.5 | 13.4 | 11.0 | 10.0 | 9.2 | 7.0 |
Selling, general and administrative | 25.0 | 12.5 | 9.7 | 7.9 | 7.4 | 6.1 | 4.4 | 4.0 |
Total operating expenses | 36.2 | 27.8 | 155.6 | 21.3 | 18.3 | 68.9 | 64.0 | 11.0 |
Loss from operations | -35.9 | -27.8 | -23.2 | -21.3 | -18.3 | -68.9 | -13.6 | -11.0 |
Operating margin | 100.0% | | -17.5% | | | | -26.9% | |
Interest income | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 |
Interest expense | -1.3 | -1.1 | -1.1 | -1.2 | -1.2 | -0.7 | -0.5 | -0.5 |
Net loss | -37.2 | -28.8 | -24.2 | -22.5 | -19.5 | -69.4 | -14.0 | -11.5 |
|
Other comprehensive income (loss): | | | | | | | | |
Unrealized net loss on marketable securities | -0.1 | | | | | | | |
Comprehensive loss | -37.3 | -28.8 | -24.2 | -22.5 | -19.5 | -69.4 | -14.0 | -11.5 |
|
Per share information: | | | | | | | | |
Net loss, basic and diluted (in dollars per share) | ($1.44) | ($1.24) | ($1.07) | ($0.99) | ($0.86) | ($3.18) | ($0.66) | ($0.62) |
|
Basic and diluted weighted average shares outstanding (in shares) | 25.9 | 23.2 | 22.5 | 22.7 | 22.7 | 21.8 | 19.2 | 18.7 |
|